Physician profile
Saad Rahman
NPI 1265434450
$5,715.39
in general payments reported to CMS, 2019-2025
29 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $290 · 2021: $349 · 2022: $683 · 2023: $1,141 · 2024: $1,367 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,634.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $970.31 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $658.67 | 2019-2024 | Veltassa |
| Amgen INC. | $450.14 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $440.83 | 2019-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $370.70 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $359.65 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $357.39 | 2019-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $332.44 | 2020-2025 | Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $249.85 | 2021-2024 | |
| Ardelyx, INC. | $215.78 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Opko Pharmaceuticals, LLC | $189.85 | 2019-2024 | Rayaldee |
| Glaxosmithkline, LLC. | $184.21 | 2020-2025 | Benlysta, Jesduvroq, Arexvy |
| Travere Therapeutics, INC. | $139.77 | 2019-2025 | |
| Medtronic, INC. | $116.23 | 2025 | Symplicity G3 |
| Alexion Pharmaceuticals, INC. | $112.04 | 2020-2023 | Soliris |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.95 | 2024-2025 | Jardiance |
| Daiichi Sankyo INC. | $62.88 | 2020-2025 | Injectafer |
| Ani Pharmaceuticals, INC. | $62.37 | 2024-2025 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $55.82 | 2024 | Auryxia, Vafseo |
| Novo Nordisk INC | $53.30 | 2025 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $48.81 | 2023 | Krystexxa |
| Lilly USA, LLC | $45.71 | 2023-2024 | Jardiance |
| Bard Peripheral Vascular, INC. | $31.53 | 2019 | |
| Baxter Healthcare | $28.55 | 2020-2021 | |
| Amicus Therapeutics, INC. | $19.94 | 2023 | Galafold |
| Mallinckrodt Enterprises LLC | $18.51 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.68 | 2019 | |
| Cycle Pharmaceuticals INC | $13.24 | 2024 | Tiopronin |
| Kyowa Kirin, INC. | $13.24 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saad Rahman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.